SCHEMBL2363449

SCHEMBL2363449

COC(=O)c1ccc(C(=O)CC(=O)c2ccc(OCCCC(C)C)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.64
RAB9A P51151 3/20 0.57
RARB P10826 1/20 0.55
MAPK1 P28482 1/20 0.54
NPC1 O15118 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
TSHR P16473 3/20 0.53
GAA P10253 2/20 0.53
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
ALDH1A1 P00352 1/20 0.51
THRB P10828 1/20 0.51
HSD17B10 Q99714 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
EPHX2 P34913 1/20 0.48
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
HPGD P15428 1/20 0.47
LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12243267 0.93 MAPT (0.66) MAPTRAB9ARARBMAPK1NPC1
SCHEMBL2363105 0.89 MAPT (0.57) MAPTRAB9ARARBMAPK1NPC1
SCHEMBL10334311 0.88 MAPT (0.68) MAPTRAB9ARARBMAPK1NPC1
SCHEMBL10334158 0.88 MAPT (0.68) MAPTRAB9ARARBMAPK1NPC1
SCHEMBL12694298 0.86 MAPT (0.74) MAPTRAB9ARARBMAPK1NPC1
SCHEMBL2350431 0.85 MAPT (0.72) MAPTRAB9ANPC1SMN1; SMN2TSHR
SCHEMBL29974918 0.84 MAPT (0.62) MAPTRAB9ARARBMAPK1NPC1
SCHEMBL2350770 0.82 MAPT (0.68) MAPTRAB9ARARBNPC1SMN1; SMN2
SCHEMBL2356406 0.81 MAPT (0.66) MAPTRAB9ARARBNPC1SMN1; SMN2
SCHEMBL2355796 0.81 MAPT (0.66) MAPTRAB9ARARBNPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921309-B2 Lipopeptide compounds and their use UNIQUEST PTY LIMITED (AU) 2014-12-30 US disclosed
EP-2350119-B1 LIPOPEPTIDE COMPOUNDS AND THEIR USE UNIQUEST PTY LTD (AU) 2014-10-29 EP disclosed
US-20110224129-A1 Lipopeptide Compounds and Their Use MERLION PHARMACEUTICALS PTE LTD (SG) 2011-09-15 US disclosed
EP-2350119-A1 LIPOPEPTIDE COMPOUNDS AND THEIR USE Merlion Pharmaceuticals Pte Ltd. (SG) 2011-08-03 EP disclosed
WO-2010062264-A1 LIPOPEPTIDE COMPOUNDS AND THEIR USE MERLION PHARMACEUTICALS PTE LTD (SG) 2010-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224129-A1 Lipopeptide Compounds and Their Use VIP, LTA, CLPTM1 MAPT 4432/4885RAB9A 2480/4885RARB 2792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.